Nuvation Bio, Inc. | Oncology Drug Development
Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company founded in 2018 by biopharma veteran David Hung, M.D. The company develops differentiated and novel oncology treatments through proprietary drug discovery programs and business development. Its lead product IBTROZI (taletrectinib) is FDA-approved for ROS1-positive non-small cell lung cancer. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2021
Oct 2019
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
